Aspect Partners’s Dyne Therapeutics DYN Stock Holding History

Aspect Partners’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.75K	Hold	233	–	–	﹤0.01%	454
2026 Q2	$5.18K	Buy	233 +8	+4%	+$149	﹤0.01%	406
2026 Q1	$4.08K	Hold	225	–	–	﹤0.01%	391
2025 Q4	$4.4K	Sell	225 -380	-63%	-$7.2K	﹤0.01%	399
2025 Q3	$7.65K	Buy	605 +580	+2,320%	+$6.62K	﹤0.01%	350
2025 Q2	$238	Hold	25	–	–	﹤0.01%	594
2025 Q1	$262	Sell	25 -700	-97%	-$10K	﹤0.01%	586
2024 Q4	$17.1K	Hold	725	–	–	0.01%	220
2024 Q3	$26K	Hold	725	–	–	0.01%	162
2024 Q2	$25.6K	Hold	725	–	–	0.02%	159
2024 Q1	$20.6K	Hold	725	–	–	0.02%	178
2023 Q4	$9.6K	Buy	+725	New	+$7.08K	0.01%	263

Other funds holding DYN

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Hilton Head Capital Partners Hilton Head Island, South Carolina $185M AUM 26.97% 1-Year Est. Return

Aspect Partners's DYN Position: Q3 2026 in Review

Aspect Partners held its Dyne Therapeutics (DYN) position steady in Q3 2026 at 233 shares worth $3.75K. The position accounts for ﹤0.01% of the portfolio, ranked #454.

Aspect Partners first reported a position in DYN in Q4 2023 and has held it in 12 quarters since. The position peaked at $26K in Q3 2024. 25 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

Aspect Partners held 233 shares of Dyne Therapeutics worth $3.75K as of Q3 2026.
Aspect Partners left its Dyne Therapeutics share count unchanged in Q3 2026.
Dyne Therapeutics made up ﹤0.01% of Aspect Partners's portfolio in Q3 2026, its #454 holding.
Aspect Partners first reported a position in Dyne Therapeutics in Q4 2023 and has held it in 12 quarters since.
Aspect Partners's Dyne Therapeutics position peaked at $26K in Q3 2024.
25 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on Aspect Partners's 13F filing for Q3 2026, filed 20 Oct 2026.